Shanghai Ruijin Hospital recently announced the official launch of an international multicenter clinical trial led by its Oncology Center. The trial targets a novel immune checkpoint inhibitor (codenamed RGX-107) for advanced solid tumors and will be conducted simultaneously at 12 top-tier medical centers in China, the United States, Europe, and Japan. RGX-107 has shown in Phase I trials a response rate improvement to 34% in various drug-resistant tumors, significantly outperforming existing regimens. As the global coordinating center, Ruijin Hospital is responsible for overall trial design and data management, planning to enroll 420 patients, with interim results expected to be published in 2026.
The trial employs an adaptive design, incorporating real-time biomarker screening to dynamically adjust dose groups, a novel process expected to shorten the drug development cycle by 18 months. Ruijin Hospital has equipped itself with fully automated liquid biopsy systems and AI-assisted imaging evaluation platforms to ensure standardized data across all centers.
Background and Significance
International multicenter trials are a critical pathway for the global simultaneous registration of innovative drugs. In the past, China often participated as a partner rather than a leader. Ruijin Hospital's leading role this time signifies international recognition of its clinical research capabilities. The National Medical Products Administration (NMPA) and the U.S. FDA have reached a preliminary agreement on mutual recognition of trial data, which will streamline subsequent reviews and enable faster approval of new drugs in China and overseas. At the press conference, the president of Ruijin Hospital stated that the center will leverage real-world data platforms to track patients' long-term survival benefits, providing more robust evidence for precision medicine.
Significance for International Patients
For international patients, this trial means access to cutting-edge candidate drugs in China simultaneously, with trial costs covered by the sponsor, significantly reducing the economic barrier to treatment. Ruijin Hospital has an International Medical Department offering multilingual support and case management, covering visa, accommodation, and follow-up arrangements. Patients meeting the enrollment criteria can complete on-site evaluation within one week after initial remote screening. Additionally, all examination data during the trial can be shared via a mobile app with the patient's home country physician, ensuring continuity of care.
How MedCare Can Help
MedCare, as a cross-border medical service platform, has established a green channel with Ruijin Hospital's International Department, assisting overseas patients in quickly matching relevant departments at Ruijin Hospital, arranging teleconsultations, and preliminary trial screening. We provide cost estimation services, clarifying potential out-of-pocket expenses outside the trial (such as imaging tests, nursing fees, etc.), and offer follow-up coordination. Through the Contact Us page, patients can submit their medical records summary, and our medical team will provide an initial assessment within 48 hours. For patients not eligible for the trial, we also offer appointment channels for other innovative therapies at Ruijin Hospital, as detailed in Medical Services and Shanghai Partner Hospitals.
Related Reading: Shanghai Partner Hospitals